Objective. Early recognition and treatment of RA is associated with an improved outcome. The 2010 ACR/ EULAR criteria for RA identify RA patients earlier than the 1987 ACR criteria. Nevertheless, we recently observed that 24% of the 2010 unclassified arthritis (UA) patients develop RA during follow-up. Here we studied this frequency in other cohorts and evaluated the prognostic accuracy of ACPA and the Leiden prediction rule in 2010 UA patients.
Introduction
Persistence of inflammation and destruction of joints are hallmarks of RA. Several observational cohort studies and clinical trials demonstrate that early initiation of treatment is associated with more remission and less joint destruction [13] . In order to initiate treatment early, adequate referral strategies are required, as well as tools that identify RA patients among all patients with early unclassified arthritis (UA) [4] . Several biomarkers have been identified, of which ACPAs are among the most potent. Combining several risk factors resulted in the construction of prediction models; of these the Leiden prediction rule is widely validated [5, 6] . However, these studies were performed in patients with UA when RA was defined using the 1987 ACR criteria.
Recently, the 2010 ACR/EULAR criteria for RA were developed. A major reason to derive new criteria was to obtain criteria that are fulfilled at an early stage of RA [7] . Current data show that the 2010 criteria are indeed fulfilled earlier than the 1987 criteria [810] . Consequently the group of patients classified as UA when the 2010 criteria are applied has changed. The so-called 2010 UA patients have milder characteristics at disease onset and as a group also have a less severe disease outcome [8, 10] . Nonetheless, not all patients who are eventually diagnosed with RA fulfil the 2010 criteria at first presentation. We recently observed that 24% of the early 2010 UA patients fulfilled the 1987 criteria during the first year of follow-up [11] . Ideally these patients should also be identified at initial presentation in order to achieve early and individualized treatment strategies.
This study aimed to evaluate (i) the proportion of 2010 UA patients who fulfil the 1987 criteria during the first year of the disease in other independent early arthritis cohorts and (ii) the prognostic value of available prognostic markers (ACPA and the Leiden prediction rule) in 2010 UA patients in all three cohorts.
Patients and methods

Patients
The study comprised early arthritis patients of three different cohorts. First, patients from the Leiden Early Arthritis Clinic (EAC) cohort were studied. This population-based longitudinal cohort started in 1993 and included patients with arthritis of at least one joint and symptom duration <2 years. At first visit, questionnaires were completed, physical examination performed, radiographs taken and blood obtained for determination of CRP, ESR, IgM-RF and ACPA. Follow-up visits were performed yearly [12] .
The second studied cohort comprised patients from the Birmingham very early arthritis clinic that started in 2000. Patients were included in cases of clinical synovitis of at least one joint and symptom duration (of any symptom attributed by the rheumatologist to inflammatory arthritis) of 43 months with no prior DMARD treatment. At baseline, demographic data, physical examination and radiographs were obtained and blood was obtained for determination of CRP, ESR, IgM-RF and ACPA. Follow-up visits were performed at 1, 2, 3, 6, 12 and 18 months [9] .
Third, early arthritis patients from the EAC at the Jan van Breemen Research Institute/Reade in Amsterdam, The Netherlands, which started in 1995, were studied. Patients were included with at least two swollen joints, symptom duration of <2 years and no prior DMARD treatment. Patients with OA, crystal arthropathy, SpA, SLE, SS and infectious arthritis were excluded. At baseline, demographic data were collected, physical examination was performed, radiographs were taken and blood was obtained for determination of CRP, ESR, IgM-RF and ACPA. Follow-up visits were performed at 3-month intervals during the first year (Table 1 ) [8] .
In all three cohorts, the baseline diagnosis was assessed. First, other diagnoses were excluded, such as ReA, PsA, crystal arthropathy, SpA, SLE and sarcoidosis. Subsequently, RA was classified according to the 2010 criteria where radiologic information was not taken into account [9, 10] . Then the remaining patients were classified as 2010 UA and were studied here. Furthermore, we evaluated which of the 2010 UA patients fulfilled the 1987 criteria at baseline. Patients who were classified as UA In the Leiden EAC cohort, some data were missing: morning stiffness, n = 37; swollen joint count (SJC), n = 22; tender joint count (TJC), n = 337; small joints involved, n = 32, symmetrical joint involvement, n = 89; upper extremity joints involved, n = 106; CRP, n = 58; ACPA, n = 143; RF, n = 10.
b In the Birmingham EAC, some data were missing: morning stiffness, n = 1; CRP, n = 4; ACPA, n = 3; RF, n = 8. In the Amsterdam EAC cohort, some data were missing: for morning stiffness, SJC, TJC, symmetrical joint involvement and upper extremity joint involvement, n = 8.
according to both the 1987 and 2010 criteria (1987 and 2010 UA patients) were also studied (see supplementary Fig. S1 for an overview, available at Rheumatology Online). All three cohorts obtained written informed consent from the participants. The studies were approved by the local medical ethic committees.
Outcome
Fulfilling the 1987 criteria during the first year of follow-up was the outcome measure studied. The 1987 criteria could be fulfilled cumulatively during follow-up. Although fulfilling the 1987 criteria may not be an early phenomenon, these criteria still reflect the core phenotype of RA. Since it can be argued that this outcome is subject to some degree of circularity, two other outcomes were studied in the Leiden dataset, DMARD initiation during the first year and disease persistency over 7 years of follow-up. Patients treated according to a randomized trial were not studied for the outcome DMARD initiation during the first year. Arthritis persistency was defined as the absence of a sustained DMARD-free remission, which was described as the absence of synovitis for at least 1 year after cessation of eventual DMARD therapy [13] .
Analysis
Analyses were done both on 2010 UA patients and 1987 and 2010 UA patients using SPSS version 17.0. The proportion of 2010 UA patients and 1987 and 2010 UA patients who progressed to RA was determined. ACPA positivity and the Leiden prediction score (grouped as score 46, >6 and <8 and 58) were evaluated in relation to the development of RA. The Leiden prediction model consists of nine items. Each prediction score varied from 0 to 14 and corresponded to the percent chance of developing RA. The higher the score, the higher the chance of progressing to RA. A score of 46 is associated with a negative predictive value (NPV) of 91% and a score 58 with a positive predictive value (PPV) of 84%. The area under the receiver operator characteristic curve (AUC) was determined; the prediction score was analysed as continuous variable.
Results
In total, 1219 2010 UA patients, originating from three different early arthritis clinics, were studied: 776 from Leiden, 121 from Birmingham and 322 from Amsterdam (see supplementary Fig. S1 for an overview, available at Rheumatology Online). In these three cohorts, 24%, 26% and 12% of the 2010 UA patients, respectively, fulfilled the 1987 ACR criteria during the first year of follow-up.
As a proportion of the 2010 UA patients fulfilled the 1987 criteria at baseline (103, 7, 86 patients in the three cohorts, respectively), progression to RA was subsequently studied in the subgroup of patients who were classified as UA according to both sets of criteria. Now 673, 114 and 236 1987 and 2010 UA patients were studied, of whom 15%, 21% and 9%, respectively, progressed to RA.
Next, we evaluated the extent to which UA patients who fulfil the 1987 criteria during follow-up could be identified at baseline using ACPA or the Leiden prediction rule. First, 2010 UA patients were studied. The frequency of ACPA positivity in the different cohorts with 2010 UA patients varied between 0% and 7%. When evaluating the prediction scores, it was observed that a prediction score of 58 was seldom obtained. The AUC of ACPA ranged between 0.49 and 0.60 and that of the prediction score between 0.59 and 0.81.
Subsequently, the 1987 and 2010 UA patients were evaluated. The frequency of ACPA positivity or high prediction scores was even lower here ( Table 2 ). This prohibited determination of PPVs and reduced the clinical utility of these markers in these patients. The NPVs of ACPA were 83%, 79% and 91%, respectively. The NPVs of prediction scores 46 were 88%, 81% and 90%, respectively. Although these NPVs seem adequate, these chances were comparable to the prior chances of not developing RA, which were 85%, 79% and 91%, respectively. The AUCs of both predictive markers ranged between 0.49 and 0.55 for the ACPA and between 0.53 and 0.78 for the prediction score (supplementary Table S1 , available at Rheumatology Online).
Since we observed that the majority of 1987 and 2010 UA patients who progressed to RA within the first year of follow-up were ACPA negative and had low prediction scores, we studied the baseline characteristics of these patients in more depth. This revealed an overall milder phenotype at baseline of 1987 and 2010 UA patients who did not progress to RA compared with those who did (supplementary Table S2 , available at Rheumatology Online).
The main outcome studied was fulfilling the 1987 ACR criteria after 1 year of follow-up. DMARD initiation during year 1 and disease persistency over 7 years (absence of sustained DMARD-free remission) were also assessed as secondary outcomes. During the first year, 39% of the 2010 UA patients and 34% of the 1987 and 2010 UA patients initiated a DMARD. Over the 7-year follow-up in the Leiden dataset, 54% of the 2010 UA patients and 53% of the 1987 and 2010 UA patients had persistent disease. However, with these outcomes the majority of patients with DMARD initiation and/or persistent arthritis were not recognized by ACPA or the prediction model, which was due to the low prevalence of ACPA and high prediction scores in these UA patients ( Table 2) .
Discussion
This study evaluated the frequency of development of RA (1987 criteria) in 2010 UA patients in three independent cohorts and showed that a large number of 2010 UA patients fulfil the 1987 criteria during follow-up. Second, it was evaluated whether ACPA or a previously derived prediction rule is useful in identifying which 2010 UA patients will progress to RA (1987). Analyses on 2010 UA patients from three clinics consistently revealed that www.rheumatology.oxfordjournals.org 133 (21) 263 (62) 141 (33) 168 (44) 200 (52) 87 (74) 30 (25) 268 (83) 39 (12) + 18 (3)
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47 (7) 26 (4) 22 (4) 21 (4) 15 (4) 15 (4) 4 (4) 6 (6) 36 (16) 2 ( the majority of patients were ACPA negative and had low prediction scores, indicating that they are not relevant prognostic markers in UA (2010 criteria). The very low frequency of ACPA positivity or of high prediction scores may be explained by the fact that ACPA and the majority of variables composing the prediction rule are also included in the 2010 criteria and hence have already been used for classification. Apparently, after having been used for risk estimation via the 2010 criteria, neither ACPA nor the prediction rule is able to subsequently identify the individual patients who are missed by the 2010 criteria.
It was observed that some of the 2010 UA patients already fulfil the 1987 criteria at baseline. These data confirm previous reports, showing that not all 1987 RA patients are classified as RA according to the 2010 criteria [9, 10] . This may suggest that it is appropriate to use both the 2010 and 1987 criteria in individual patients. Finally, we studied 1987 and 2010 UA patients; the findings regarding ACPA and the prediction rule in these patients were comparable to those in the 2010 UA patients.
A strength of the present study is that three different early arthritis cohorts were studied. These cohorts had slightly different inclusion and exclusion criteria, which can be seen as a limitation. Despite this heterogeneity, the observed findings were remarkably similar between cohorts, strengthening the validity of the findings and the conclusion that ACPA and the Leiden prediction rule are not accurate prognostic tools in 2010 UA patients.
There are several caveats to this study. A potential drawback is that the replication cohorts were smaller than the first cohort. On the other hand, as mentioned, the trend in the data is comparable in all three cohorts, suggesting that the results regarding ACPA and the prediction rule are not false negatives. Second, a majority of the patients studied were enrolled when aggressive DMARD treatment of UA was uncommon. Nonetheless, we cannot exclude that some of the patients who were classified as not fulfilling the 1987 criteria during follow-up are misclassified due to DMARD treatment. This implies that the actual proportion of UA patients who have an early form of RA is even higher. However, in this scenario, the conclusions regarding the studied predictive markers would not change. Third, in a portion of the Leiden patients, ACPA data were not available, especially on those UA patients who did not progress to be 1987 criteria positive over time. Theoretically some of the patients may have been falsely classified as 2010 UA at baseline. However, considering the similarity in results between the cohorts, this influence is probably small.
In conclusion, a proportion of 1987 RA patients were not identified at baseline by the 2010 criteria. Assuming also that in UA patients who fulfil the RA criteria later in time a window of opportunity effect is present, these patients are preferably identified at baseline to this end. The ACPA test and the Leiden prediction rule are also not useful in identifying these patients. Hence other prognostic markers are needed with significantly different sensitivity and specificity characteristics to clinical examination; these may include imaging modalities such as ultrasound or extremity MRI [14, 15] .
Rheumatology key messages
. During the first year 1216% of 2010 patients progress to RA. . 2010 UA patients who progress to RA could not be identified by ACPA status or the Leiden prediction rule. . DMARD therapy should not be withheld from 2010 UA patients just because they do not fulfil the 2010 criteria.
